Trovagene, Inc. Form 8-K June 10, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2015

Trovagene, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)

001-3558 (Commission File Number) 27-2004382 IRS Employer Identification No.)

11055 Flintkote Avenue, Suite A

San Diego, CA 92121

(Address of principal executive offices)

Registrant s telephone number, including area code: (858) 952-7570

Edgar Filing: Trovagene, Inc. - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form	8-K filing is intended to simultaneously	satisfy the filing obligation of t	he registrant under any of
the following provisions:			

- o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders

On June 10, 2015, Trovagene, Inc. (the Company) held its Annual Meeting of Stockholders (the Annual Meeting). A total of 16,417,523 shares of common stock, constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on April 20, 2015, as supplemented, are as follows:

Proposal 1. All of the eight (8) nominees for director were elected to serve until the 2016 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director s earlier resignation, removal or death. The result of the votes to elect the eight (8) directors was as follows:

Directors	For	Against	Abstain	Broker Non Vote
Dr. Paul Billings	8,985,194	0	64,438	7,367,891
Gary S. Jacob	5,829,839	0	3,219,793	7,367,891
Thomas H. Adams	5,727,759	0	3,321,873	7,367,891
John P. Brancaccio	5,835,339	0	3,214,293	7,367,891
Antonius Schuh	8,984,601	0	65,031	7,367,891
Dr. Stanley Tennant	8,985,194	0	64,438	7,367,891
Dr. Rodney S. Markin	8,985,194	0	64,438	7,367,891
Carl Feldbaum	8,984,394	0	65,238	7,367,891

Proposal 2. The appointment of BDO USA, LLP as the Company s independent registered public accounting firm for its fiscal year ended December 31, 2015 was ratified and approved by the stockholders by the votes set forth in the table below:

For	Against	Abstain	Broker Non Vote
16.148.	489 152.853	116.18	81

Proposal 3. The adoption of an amendment to the Company s 2014 Equity Incentive Plan to increase the number of shares reserved for issuance thereunder to 5,000,000 shares from 2,500,000 shares of common stock was ratified and approved by the stockholders by the votes set forth in the table below:

For	Against	Abstain	Broker Non Vote
8,130,153	872,655	46,824	7,367,891

Edgar Filing: Trovagene, Inc. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 10, 2015

TROVAGENE, INC.

By:

/s/ Antonius Schuh Antonius Schuh Chief Executive Officer

3